A state is trying to revive a ban on pharma ‘price gouging’
New Hampshire is revisiting a “price gouging” ban after a court struck down Maryland’s version — and other states could follow.
Related Articles
SalioGen Therapeutics hit by layoffs, as gene-editing biotechs continue to struggle
SalioGen Therapeutics, a company that raised $135 million to develop a new gene-editing technology, has instituted widespread layoffs and is scaling back its ambitions.
Does AI make patient portal responses better? Depends on who you ask
In latest health tech news: Why nurses liked an AI bot more than doctors did, payers, employers to boost digital health spend, and more.
UnitedHealthcare rolls out new therapy restrictions for Medicare Advantage plans
As of Sept. 1, Medicare Advantage members who need PT, OT, or ST in a physician’s office will need approval from UnitedHealthcare. This will create…
130,000 U.S. cancer cases went undiagnosed in Covid pandemic, study finds
130,000 U.S. cancer cases went undiagnosed in the Covid pandemic. Experts still don’t know what happened to them.
In children, Covid is tied to higher risk of type 2 diabetes
It may be time to add Covid-19 infection to the list of possible risk factors for developing type 2 diabetes at a young age. An…
Yes on abortion, no on Tester? A Democratic senator’s struggle underscores his party’s conundrum
Montana’s role as a safe haven for abortion care in the rural West is at stake in November’s election.
2024 STAT Summit
The STAT Summit is back in Boston October 16 & 17, 2024 — this year we’re examining change in medicine, why it’s so hard, &…
Morning Rounds: Why aren’t we doing better on cardiovascular health?
Today’s health news includes how the U.S. primary care crisis is hurting the fight against heart disease, the Nobel gender gap, and more.
The biotech news you missed this weekend
Just in the first half of 2024, over $1.7 billion was committed to autoimmune disease research. The influx is driven largely by breakthroughs in CAR-T…
What the Sandoz CEO is thinking about the 2024 elections
“Railing against ‘Big Pharma’ while failing to support the market for generic and biosimilar medicines is missing the forest for the trees,” writes Sandoz CEO…